カテゴリ： GlobalData, 企業調査, 日本

Otsuka Pharmaceutical Co Ltd-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Otsuka Pharmaceutical Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8014361
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月22日
◆ページ数：102
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：日本
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Otsuka Pharmaceutical Co Ltd (OPC), a subsidiary of Otsuka Holdings Co Ltd is a provider of healthcare products. The company offers products which include pocari sweat, pocari sweat ion water, oronamin c, calorie mate, nature made, jerubure, jarinea, five mini, amino-value, enerugen, jog mate protein jelly, metro mint, the calcium, oronine and new sararin, among others. Its pharmaceutical products are used in the areas of central nervous system, cardiovascular, circulatory disease, infectious diseases, kidney, digestive disease, ophthalmology and dermatology. The company operates in the US, Japan, Belgium, Australia, the UK, Denmark, and others. OPC is headquartered in Tokyo, Japan.

Otsuka Pharmaceutical Co Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Otsuka Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 11
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 17
Partnerships 17
Ribomic Enters into Agreement with Seikagaku 17
Medibio Enters into Agreement with Otsuka Pharma 18
Ribomic Enters into Research Agreement with Astellas Pharma 19
Ribomic Enters into Research Agreement with Evec 20
Cambridge Isotope Laboratories Enters into Agreement with IROA Technologies 21
Otsuka Pharma Enters into Co-Development Agreement with NEC 22
RIKEN and Otsuka Pharma Forms Joint Venture 23
Earth Chemical to Enter into Agreement with Taiko Pharma 24
Astex Pharma Enters into Agreement with Genentech 25
Ariad Pharma Enters into Co-Marketing Agreement with Otsuka Pharma for Iclusig 26
Ribomic Extends Research Agreement with Otsuka Pharma 28
Probi Enters into Co-Marketing Agreement with Pharmavite 29
Horizon Discovery Enters into Development and Commercialization Agreement with Otsuka Pharma 30
Otsuka Enters Into Co-Promotion Agreement With Takeda For TAK-438 31
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma For Lu AF20513 32
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 33
Avanir Pharma Enters Into Agreement With Merck To Promote Diabetes Drugs 34
Otsuka Pharma Enters Into Co-Promotion Agreement Lundbeck For Abilify 36
Otsuka Pharma Forms Joint Venture With Abdi Ibrahim To Market Otsuka’s Drugs In Turkey 37
Astex Pharma, Cancer Research Technology And Newcastle University Enter Into Drug Discovery Agreement 38
Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 40
Otsuka Pharma Amends Co-Development Agreement With UCB 42
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 44
Proteros Biostructures Enters Into Drug Discovery Agreement With SuperGen 46
Licensing Agreements 47
Mylan Pharma Enters into Licensing Agreement with Otsuka Novel Products for Delamanid 47
R-Pharm Enters into Licensing Agreement with Otsuka Novel Products 48
Otsuka Pharma Enters into Licensing Agreement with Teva Pharma for TEV-48125 49
Otsuka Pharma to Enter into Licensing Agreement with Ribomic for RBM001 50
Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics for Vadadustat 51
Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics 53
Otsuka Pharma Enters into Licensing Agreement with Takara Bio 54
Medimetriks Pharma Enters into Licensing Agreement with Otsuka Pharma for OPA-15406 55
Fujimoto Pharma Enters into Licensing Agreement with Ribomic 56
Lundbeck Enters Into Licensing Agreement With Otsuka Pharma For Lu AE58054 57
Concert Pharma Enters Into Licensing Agreement With AVANIR Pharma For Neurology And Psychiatry Drugs 58
NuView Life Sciences Enters into Licensing Agreement with Otsuka Pharma for VPAC1 Biomarker 60
Otsuka Pharma Enters Into Licensing Agreement With Eisai 61
Avanir Pharma And OptiNose Enter Into Licensing Agreement For Treatment Of Acute Migraine 62
Proteus Biomedical Enters Into Licensing Agreement With Otsuka Pharma 64
Otsuka Pharma Enters Into Licensing Agreement With Kyowa Hakko Kirin For Saxagliptin 65
Equity Offering 66
Taiko Pharma to Raise Funds through Private Placement of Shares 66
Avanir Pharma Raises USD230 Million in Public Offering of Shares 67
Ribomic Raises USD26 Million in IPO of Shares 69
GlycoNex Announces Private Placement Of Shares For US$9.2 Million 70
Avanir Pharma Files Registration Statement For Public Offering Of Securities For Up To US$150 Million 71
Avanir Pharma Increases Size Of Private Placement Of Shares For US$80 Million 72
Astex Pharma Files Registration Statement For Public Offering Of Securities For US$200 Million 73
Asset Transactions 75
Tolero Pharma Acquires Drug Development Assets From Astex Pharma 75
Acquisition 77
Otsuka Pharma to Acquire Neurovance 77
Otsuka Acquires Avanir Pharma for USD3.5 Billion 78
Egypt Otsuka Pharmaceutical to Acquire 80% Stake in Ateco Pharma 80
Otsuka Pharma Completes Acquisition Of Astex Pharma For US$886 Million 81
Gimv Sells Stake In Astex Therapeutics 83
China Otsuka Pharmaceutical Acquires Dalian Taihua Pharmaceutical 84
SuperGen Completes Acquisition Of Astex Therapeutics 85
Otsuka Pharmaceutical Co Ltd – Key Competitors 88
Otsuka Pharmaceutical Co Ltd – Key Employees 89
Otsuka Pharmaceutical Co Ltd – Locations And Subsidiaries 90
Head Office 90
Other Locations & Subsidiaries 90
Joint Venture 95
Recent Developments 96
Government and Public Interest 96
Jun 06, 2016: GHIT Fund Welcomes Ten New Partnerships With FUJIFILM, Otsuka, GSK, Johnson & Johnson, Kyowa Hakko Kirin, Merck, Mitsubishi Tanabe, Nipro, Sumitomo Dainippon Pharma and Salesforce.com 96
Product News 98
May 09, 2016: Introducing Three New Flavors of Calorie Mate Jelly Focusing on the Need for a Nutritionally Balanced Jelly Beverage Option 98
01/07/2016: Neurovance Appoints Jeff Bailey to Chair Its Board of Directors 99
Clinical Trials 100
Jul 27, 2016: Neurovance Announces Positive Centanafadine Phase 2b Results for Adult ADHD, and Plans for Phase 3 Trials 100
Jan 07, 2016: Neurovance Announces Series of Three Clinical Trials to Support Advanced Development of Centanafadine (CTN) in Adult ADHD 101
Appendix 102
Methodology 102
About GlobalData 102
Contact Us 102
Disclaimer 102

List of Tables
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Otsuka Pharmaceutical Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 10
Otsuka Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 11
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Ribomic Enters into Agreement with Seikagaku 17
Medibio Enters into Agreement with Otsuka Pharma 18
Ribomic Enters into Research Agreement with Astellas Pharma 19
Ribomic Enters into Research Agreement with Evec 20
Cambridge Isotope Laboratories Enters into Agreement with IROA Technologies 21
Otsuka Pharma Enters into Co-Development Agreement with NEC 22
RIKEN and Otsuka Pharma Forms Joint Venture 23
Earth Chemical to Enter into Agreement with Taiko Pharma 24
Astex Pharma Enters into Agreement with Genentech 25
Ariad Pharma Enters into Co-Marketing Agreement with Otsuka Pharma for Iclusig 26
Ribomic Extends Research Agreement with Otsuka Pharma 28
Probi Enters into Co-Marketing Agreement with Pharmavite 29
Horizon Discovery Enters into Development and Commercialization Agreement with Otsuka Pharma 30
Otsuka Enters Into Co-Promotion Agreement With Takeda For TAK-438 31
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma For Lu AF20513 32
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 33
Avanir Pharma Enters Into Agreement With Merck To Promote Diabetes Drugs 34
Otsuka Pharma Enters Into Co-Promotion Agreement Lundbeck For Abilify 36
Otsuka Pharma Forms Joint Venture With Abdi Ibrahim To Market Otsuka’s Drugs In Turkey 37
Astex Pharma, Cancer Research Technology And Newcastle University Enter Into Drug Discovery Agreement 38
Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 40
Otsuka Pharma Amends Co-Development Agreement With UCB 42
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 44
Proteros Biostructures Enters Into Drug Discovery Agreement With SuperGen 46
Mylan Pharma Enters into Licensing Agreement with Otsuka Novel Products for Delamanid 47
R-Pharm Enters into Licensing Agreement with Otsuka Novel Products 48
Otsuka Pharma Enters into Licensing Agreement with Teva Pharma for TEV-48125 49
Otsuka Pharma to Enter into Licensing Agreement with Ribomic for RBM001 50
Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics for Vadadustat 51
Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics 53
Otsuka Pharma Enters into Licensing Agreement with Takara Bio 54
Medimetriks Pharma Enters into Licensing Agreement with Otsuka Pharma for OPA-15406 55
Fujimoto Pharma Enters into Licensing Agreement with Ribomic 56
Lundbeck Enters Into Licensing Agreement With Otsuka Pharma For Lu AE58054 57
Concert Pharma Enters Into Licensing Agreement With AVANIR Pharma For Neurology And Psychiatry Drugs 58
NuView Life Sciences Enters into Licensing Agreement with Otsuka Pharma for VPAC1 Biomarker 60
Otsuka Pharma Enters Into Licensing Agreement With Eisai 61
Avanir Pharma And OptiNose Enter Into Licensing Agreement For Treatment Of Acute Migraine 62
Proteus Biomedical Enters Into Licensing Agreement With Otsuka Pharma 64
Otsuka Pharma Enters Into Licensing Agreement With Kyowa Hakko Kirin For Saxagliptin 65
Taiko Pharma to Raise Funds through Private Placement of Shares 66
Avanir Pharma Raises USD230 Million in Public Offering of Shares 67
Ribomic Raises USD26 Million in IPO of Shares 69
GlycoNex Announces Private Placement Of Shares For US$9.2 Million 70
Avanir Pharma Files Registration Statement For Public Offering Of Securities For Up To US$150 Million 71
Avanir Pharma Increases Size Of Private Placement Of Shares For US$80 Million 72
Astex Pharma Files Registration Statement For Public Offering Of Securities For US$200 Million 73
Tolero Pharma Acquires Drug Development Assets From Astex Pharma 75
Otsuka Pharma to Acquire Neurovance 77
Otsuka Acquires Avanir Pharma for USD3.5 Billion 78
Egypt Otsuka Pharmaceutical to Acquire 80% Stake in Ateco Pharma 80
Otsuka Pharma Completes Acquisition Of Astex Pharma For US$886 Million 81
Gimv Sells Stake In Astex Therapeutics 83
China Otsuka Pharmaceutical Acquires Dalian Taihua Pharmaceutical 84
SuperGen Completes Acquisition Of Astex Therapeutics 85
Otsuka Pharmaceutical Co Ltd, Key Competitors 88
Otsuka Pharmaceutical Co Ltd, Key Employees 89
Otsuka Pharmaceutical Co Ltd, Other Locations 90
Otsuka Pharmaceutical Co Ltd, Subsidiaries 90
Otsuka Pharmaceutical Co Ltd, Joint Venture 95

★海外企業調査レポート[Otsuka Pharmaceutical Co Ltd-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Oriola-KD Oyj (OKDBV)：企業の財務・戦略的SWOT分析
    Oriola-KD Oyj (OKDBV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Edge Therapeutics Inc (EDGE)：製薬・医療：M&Aディール及び事業提携情報
    Summary Edge Therapeutics Inc (Edge Therapeutics) is a clinical-stage biotechnology company that discovers, develops and commercializes hospital-based therapies. The company offers hospital based therapies capable of transforming treatment paradigms in the management of life-threatening, acute neuro …
  • Neomed Institute：製薬・医療：M&Aディール及び事業提携情報
    Summary Neomed Institute (Neomed) is a not-for-profit organization that provides drug discovery and development services. The organization spans its expertise in the development of small molecule therapeutics, biologics and vaccines. It offers chemistry, DMPK, fermentation and biology laboratories, …
  • Centene Corp (CNC)：企業の財務・戦略的SWOT分析
    Centene Corp (CNC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Hotel Royal Limited：企業の戦略・SWOT・財務情報
    Hotel Royal Limited - Strategy, SWOT and Corporate Finance Report Summary Hotel Royal Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Seair, Inc. (SDS)-石油・ガス分野：企業M&A・提携分析
    Summary Seair, Inc. (Seair) is a clean technology company that carries out research and development, production and sale of diffusion and sterilization technologies. It focuses on commercializing advanced waste water and industrial fluid treatment solutions. The company offers high performance propr …
  • Safran SA：企業の戦略・SWOT・財務情報
    Safran SA - Strategy, SWOT and Corporate Finance Report Summary Safran SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Liquor Control Board of Ontario：企業の戦略的SWOT分析
    Liquor Control Board of Ontario - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • SunTech Medical Inc：医療機器：M&Aディール及び事業提携情報
    Summary SunTech Medical Inc (SunTech) is a medical device company that manufactures and markets clinical-grade non-invasive blood pressure monitoring products and technologies. The company provides products such as ambulatory blood pressure monitoring products, blood pressure w and vitals, blood pre …
  • Saputo Dairy UK Ltd：企業の戦略的SWOT分析
    Saputo Dairy UK Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Sun-Rype Products Ltd.：企業の戦略・SWOT・財務情報
    Sun-Rype Products Ltd. - Strategy, SWOT and Corporate Finance Report Summary Sun-Rype Products Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Biofortuna Ltd：医療機器：M&Aディール及び事業提携情報
    Summary Biofortuna Ltd (Biofortuna) is a provider of contract services and molecular diagnostic products. The company distributes CE-marked and freeze-dried PCR diagnostic kits. It has freeze dried molecular diagnostic products targeted at the transplantation, disease identification and pharmacogene …
  • Kuwait Petroleum Corporation：企業の戦略的SWOT分析
    Kuwait Petroleum Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Western Gas Partners LP (WES)：企業の財務・戦略的SWOT分析
    Summary Western Gas Partners LP (Western Gas), a subsidiary of Anadarko Petroleum Corp is an oil and gas company that acquires, owns, develops and operates midstream energy assets. The company's services include processing, compressing, gathering, treating and transporting natural gas, natural gas l …
  • Japan Foods Co Ltd：企業の戦略・SWOT・財務分析
    Japan Foods Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Japan Foods Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • MEG Energy Corp (MEG)：石油・ガス：M&Aディール及び事業提携情報
    Summary MEG Energy Corp (MEG) is an oil and gas company that develops and produces from oil sands. The company operates Christina lake, May River and Surmont project. Its technologies comprise steam-assisted gravity drainage, cogeneration, Hi-Q field pilot and eMSAGP. MEG's Christina Lake project is …
  • FieldPoint Petroleum Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q3, 2017
    FieldPoint Petroleum Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2017 Summary FieldPoint Petroleum Corp (FieldPoint) is an oil and gas company that acquires, operates and develops oil and gas properties. The company’s acquisition includes leasehold and working intere …
  • Rosneft Oil Co (ROSN)：電力：M&Aディール及び事業提携情報
    Summary Rosneft Oil Company (Rosneft) is a vertically integrated oil and gas company that explores for, develops and produces crude oil, natural gas and condensates; and refines, markets and distributes petroleum products and petrochemicals. It has exploration assets across Western Siberia, Eastern …
  • Sony Corporation：企業の戦略・SWOT・財務情報
    Sony Corporation - Strategy, SWOT and Corporate Finance Report Summary Sony Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Particle Sciences Inc-製薬・医療分野：企業M&A・提携分析
    Summary Particle Sciences Inc (Particle Sciences), a subsidiary of The Lubrizol Corp is a contract research organization that offers complete formulation, analytic, bioanalytic and clinical trial material manufacturing solutions. The organization concentrates on BCS II/III/IV molecules, biologics an …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆